Gsk pharma shares: Pharma sector giant Glaxosmithkline Pharma (GSK Pharma) shares showed a boom for the second consecutive day. It has strengthened 29% in two days. GSK Pharma’s shares on a trading day earlier reached ₹ 2421.30 of 20% in Intra-Day. Talking about today, more than 17 percent jumped in intra-day on the spectacular result of the December quarter. Despite the profits, the shares remain strong and today it has closed at ₹ 2608.00 with a rise of 11.82% on BSE. It reached ₹ 2744.95 with a rise of 17.70% in intra-day.
Talking about the speed of shares in a year, it rose more than 69% in a one -year low of one year on 15 April 2024 last year to reach a record high of ₹ 3087.95 on 22 August 2024. Currently, it is about 19 percent of this highs.
How was the December quarter for GSK Pharma?
In the December quarter, GSK Pharma received a consalted net profit of ₹ 230 crore. In the same quarter of the last financial year, the company had received a net profit of ₹ 46 crore, ie it gained more than 400% on an annual basis. During this period, the company’s operational revenue jumped 18% to ₹ 949 crore. However, due to the change in the product mix, the gross margin slipped to 1.50 percentage point to 62.2%.
What is the trend of brokerage?
Domestic brokerage firm ICICI Securities has increased the EPS estimate of 2026 EPS to 5-6% on GSK Pharma’s best outlook. The brokerage firm has upgraded to its rating. However, the target price has been reduced from ₹ 2,550 to ₹ 2,250. Another domestic brokerage firm Motilal Oswal increased its earnings estimates by 2% for FY 2025, 5% for FY 2026 and 7% for FY 2027. The brokerage firm did this on efforts to launch and increase the vaccine business with cancer therapy. However, Motilal Oswal has retained its neutral rating and the target price is ₹ 2,170.
This causes JPMorgan Fida, Share Rocket, 4% Strong Jump on Persistent Systems
Gainers & Losers: Sensex’s Weekly expiry, Easemytrip and ZOMATO
Disclaimer: Advice or idea experts/brokerage firms on Moneycontrol.com have their own personal views. The website or management is not responsible for this. Moneycontrol advises to users that always seek the advice of certified experts before taking any investment decision.